Core Viewpoint - A class action lawsuit has been filed against uniQure N.V. for allegedly misleading investors regarding the progress of its clinical trials, particularly concerning its lead product candidate AMT-130 for Huntington's disease [1][3]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who acquired uniQure securities between September 24, 2025, and October 31, 2025 [1][2]. - Investors have until April 13, 2026, to seek appointment as lead plaintiff representatives [2]. Group 2: Company Background - uniQure is a biotechnology company based in Amsterdam, focusing on gene therapies for rare and severe diseases [2]. - The company's lead product candidate, AMT-130, is currently in clinical trials for Huntington's disease [2]. Group 3: Allegations and Market Impact - The complaint alleges that uniQure misled investors about the design and progress of the Pivotal Study, creating an impression that accelerated approval was likely [3]. - Following the announcement of positive topline results on September 24, 2025, uniQure's shares surged nearly 250% in a single trading session [3]. - On November 3, 2025, the company disclosed that the FDA did not accept the Phase I/II study data for a BLA submission, resulting in a nearly 50% drop in share price from $67.69 on October 31, 2025, to $34.29 on November 3, 2025 [4].

Company Overview - uniQure's stock experienced a significant decline after the company reported no progress in its Type A meeting with the FDA regarding its AMT-130 treatment for Huntington's disease [1] Investment Strategy - Narweena, an asset management firm, focuses on identifying market dislocations caused by misunderstandings of long-term business prospects, aiming for excess risk-adjusted returns through secular growth opportunities in markets with entry barriers [1] - The firm emphasizes a research process centered on company and industry fundamentals to uncover unique insights, with a high risk appetite and a long-term investment horizon targeting deeply undervalued stocks [1] Market Dynamics - An aging population with low growth and stagnating productivity is expected to create new investment opportunities, contrasting with past trends [1] - Many industries may face stagnation or secular decline, which could paradoxically enhance business performance due to reduced competition [1] - The economy is increasingly influenced by asset-light businesses, leading to a declining need for infrastructure investments, resulting in a limited set of investment opportunities driving up asset prices and compressing risk premia over time [1]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased ordinary shares of uniQure N.V. during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought uniQure shares between September 24, 2025, and October 31, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the court to serve as lead plaintiff by April 13, 2026 [3]. - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [6]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting their own achievements in this area [4]. - The firm has secured significant settlements for investors, including over $438 million in 2019, and has been recognized as a leader in the field of securities class action litigation [4]. Group 3: Case Allegations - The lawsuit alleges that uniQure misrepresented the approval status of its Pivotal Study by the FDA and downplayed the likelihood of delays in its Biologics License Application (BLA) timeline [5]. - It is claimed that the defendants' statements regarding uniQure's business and prospects lacked a reasonable basis, leading to investor damages when the true information became public [5].

Core Insights - uniQure N.V. reported a narrower quarterly loss of 56 cents per share, outperforming the analyst consensus estimate of 94 cents per share [1] - The company achieved quarterly sales of $5.568 million, exceeding the analyst consensus estimate of $5.204 million [1] FDA Guidance - The FDA advised against using Phase 1/2 study data as primary evidence for the marketing application of AMT-130, a gene therapy for Huntington's disease [2] - The FDA recommended that uniQure conduct a prospective, randomized, double-blind, sham surgery-controlled study to proceed with the application [2] Stock Performance and Analyst Reactions - Following the earnings announcement and FDA guidance, uniQure shares fell by 13.3%, trading at $9.12 [2] - Mizuho analyst downgraded uniQure from Outperform to Neutral, lowering the price target from $33 to $12 [3] - Chardan Capital analyst maintained a Buy rating but reduced the price target from $53 to $16 [3]

Core Viewpoint - uniQure N.V. reported better-than-expected fourth-quarter results, with losses narrower than analyst estimates and sales exceeding expectations [1][2]. Financial Performance - The company reported quarterly losses of $0.56 per share, beating the analyst consensus estimate of losses of $0.94 per share [1]. - Quarterly sales amounted to $5.568 million, surpassing the analyst consensus estimate of $5.204 million [1]. Regulatory Update - The FDA advised against using Phase 1/2 study data as primary evidence for the marketing application of AMT-130, a gene therapy for Huntington's disease [2]. - The FDA recommended that uniQure conduct a prospective, randomized, double-blind, sham surgery-controlled study to proceed with the application [2]. Stock Market Reaction - Following the earnings announcement and regulatory news, uniQure shares dipped by 13.3%, trading at $9.12 [2]. Analyst Ratings - Mizuho analyst Uy Ear downgraded uniQure from Outperform to Neutral, lowering the price target from $33 to $12 [3]. - Chardan Capital analyst Daniil Gataulin maintained a Buy rating but reduced the price target from $53 to $16 [3].

Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. This article is intended to provide informational content and should not be viewed as an exhaustive a ...

Luca Issi from RBC Capital set a price target of $11 for UniQure (NASDAQ:QURE), indicating a potential upside of approximately 7.32%.The FDA's decision on insufficient trial data for marketing application has significantly impacted UniQure's stock price.Despite recent challenges, UniQure's market capitalization of approximately $646.84 million and a trading volume of 16,764,186 shares reflect ongoing investor interest.UniQure (NASDAQ:QURE) is a biotechnology company focused on developing gene therapies for ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased ordinary shares of uniQure N.V. during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought uniQure shares between September 24, 2025, and October 31, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by April 13, 2026 [3]. - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4]. Group 2: Case Allegations - The lawsuit alleges that uniQure misrepresented and/or failed to disclose critical information regarding the design of its Pivotal Study for a drug candidate targeting Huntington's Disease, including the lack of full FDA approval [5]. - It is claimed that uniQure downplayed the likelihood of needing to delay its Biologics License Application (BLA) timeline due to the necessity of additional studies [5]. - The lawsuit asserts that the defendants' statements regarding uniQure's business and prospects lacked a reasonable basis, leading to investor damages when the true information became public [5].

Core Viewpoint - uniQure BV is a biotechnology company focused on gene therapies for genetic disorders, facing a competitive landscape and recent downgrade by RBC Capital from "Outperform" to "Sector Perform" [1][5] Financial Performance - The company reported a quarterly loss of $0.56 per share, which was better than the Zacks Consensus Estimate of a $0.93 loss, resulting in an earnings surprise of approximately 39.91% [2][5] - Compared to the previous year's loss of $1.50 per share, this represents a notable improvement [2] Revenue Performance - uniQure reported revenues of $5.57 million for the quarter ending December 2025, missing the Zacks Consensus Estimate by 21.2% [3][5] - This revenue figure shows a slight increase from $5.22 million reported a year ago, but the company has consistently failed to meet consensus revenue estimates over the past four quarters [3] Stock Performance - The current stock price for QURE is $10.55, reflecting a significant decrease of 32.50% from its previous high [4] - The stock has fluctuated between $8.96 and $10.58 today, with a 52-week high of $71.50 and a low of $7.76 [4] - The company's market capitalization is approximately $649.9 million, with a trading volume of 13,733,434 shares on the NASDAQ exchange [4]

Core Viewpoint - A securities fraud lawsuit has been filed against uniQure N.V. following significant declines in its stock price due to insufficient clinical data for its AMT-130 gene therapy for Huntington's disease [1][2]. Group 1: Stock Performance - Shares of uniQure fell over 35% on March 2, 2026, after the U.S. FDA indicated that the clinical data for AMT-130 was inadequate for a marketing application [2]. - The decline on March 2 followed a previous drop of up to 66% on November 3, 2025, when the company disclosed prior FDA feedback regarding its clinical data [2]. Group 2: Legal Action - A securities class action has been filed in the U.S. District Court for the Southern District of New York, alleging that uniQure and certain executives misled investors about the clinical results and regulatory prospects from September 24, 2025, to October 31, 2025 [2]. - Investors who purchased uniQure common stock during this period and experienced losses may be eligible to participate in the lawsuit [3]. Group 3: Next Steps for Investors - The deadline to seek appointment as lead plaintiff in the class action is April 13, 2026, and a class has not yet been certified [4]. - Investors are encouraged to contact Block & Leviton for more information on how to proceed if they have lost money on their investment [4]. Group 4: Whistleblower Information - Individuals with non-public information about uniQure N.V. are encouraged to assist in the investigation or file a report with the SEC under the whistleblower program, potentially receiving rewards of up to 30% of any successful recovery [5]. Group 5: About Block & Leviton - Block & Leviton is recognized as a leading securities class action firm, having recovered billions for defrauded investors and representing many top institutional investors [6].